Abstract
Subclinical hyperthyroidism is defined as serum thyroid hormone levels within their respective reference ranges in the presence of low-undetectable serum thyrotropin-stimulating hormone levels. Subclinical hyperthyroidism is associated with important cardiovascular risk factors and negative effects on bone metabolism and structure. However, there are conflicting results on cardiovascular mortality and the risk of bone fractures. Treatment and management of subclinical hyperthyroidism is controversial. This article will address the necessity to treat this disorder in relation to the cause of hyperthyroidism, the patient’s age, the degree of thyroid-stimulating hormone suppression and the presence of comorbidities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
